IP Library › Granted Patent US 7,408,031
Granted Patent B2
US 7,408,031 · App. 11/670,830 · Granted Aug 5, 2008

Peptide epitopes recognized by disease promoting CD4+ T lymphocytes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,408,031
App. No.
11/670,830
Granted
Aug 5, 2008
Kind
B2
Abstract

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

Claims (7)

1. An isolated peptide that is less than 26 amino acid residues in length and binds to HLA-DR4, comprising a sequence AYQAEPNT (SEQ lID NO:49).

2. The isolated peptide of claim 1 , consisting of the amino acid sequence AYQAEPNTCATAQ (SEQ ID NO:17).

3. The isolated peptide of claim 1 , consisting of the amino acid sequence LCAYQAEPNTCATAQG (SEQ ID NO:18).

4. The isolated peptide of claim 1 , consisting of the amino acid sequence LAKEWQALCAYQAEPNT (SEQ ID NO:19).

5. The isolated peptide of claim 1 , consisting of the amino acid sequence AYQAEPNTCATAQGEGNIK (SEQ ID NO:20).

6. The isolated peptide of claim 1 , consisting of the amino acid sequence WQALCAYQAEPNTCATAQ (SEQ ID NO:2 1).

7. The isolated peptide of claim 1 , consisting of the amino acid sequence LAKEWQALCAYQAEPNTCATAQGE (SEQ ID NO:22).